US EditionPublished • loading... • Updated
Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates
The collaboration combines antibody discovery and radiopharmaceutical expertise to develop radionuclide drug conjugates that target tumors and reduce healthy tissue damage, aiming for safer cancer therapies.
- Harbour BioMed and Yantai Lannacheng agreed to collaborate on next-generation radionuclide drug conjugates, aiming to develop targeted cancer therapies from Shanghai, Cambridge, and Rotterdam.
- To accelerate better cancer care, the partners say the collaboration aims to develop precise, effective and safe therapies integrating diagnosis and treatment for patients worldwide.
- Harbour BioMed highlighted its Harbour Mice platform, noting it generates fully human antibodies in both H2L2 and HCAb formats and its HBICE and HBICA bispecific technologies enable novel tumor-killing modalities.
- Supported by Dongcheng Biochem, Lannacheng emphasizes its R&D and manufacturing, including pharmacokinetic optimization, dual-targeting platforms, and a GMP facility in Yantai, founded in 2021.
- Technically, RDCs differ because they use tumor antigen-specific ligands to deliver radionuclides directly to lesions, reducing healthy-tissue damage versus conventional radiotherapy; radionuclides may also affect neighboring tumor cells and the tumor microenvironment, potentially overcoming heterogeneity and resistance, the partners said.
Insights by Ground AI
47 Articles
47 Articles
The Berkshire Eagle+46 Reposted by 46 other sources
Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Dec. 28, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it has entered into…
Coverage Details
Total News Sources47
Leaning Left5Leaning Right5Center19Last UpdatedBias Distribution66% Center
Bias Distribution
- 66% of the sources are Center
66% Center
L 17%
C 66%
R 17%
Factuality
To view factuality data please Upgrade to Premium
